Alaunos Therapeutics, Inc.
TCRTDrugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
10dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
TCRT Earnings Report
FQ end 2026-06
How TCRT's past catalysts played out
doxorubicin in combination with palifosfamide-tris
Soft Tissue Sarcoma
Darinaparsin
Hematologic Neoplasms
ZIO-201
Advanced Sarcoma
INXN-2001
Melanoma
ZIO-101 (Darinaparsin)
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
doxorubicin in combination with palifosfamide-tris | Phase 3 | Soft Tissue Sarcoma | - | - |
Darinaparsin | Phase 2 | Hematologic Neoplasms | - | - |
ZIO-201 | Phase 2 | Advanced Sarcoma | - | - |
INXN-2001 | Phase 2 | Melanoma | - | - |
ZIO-101 (Darinaparsin) | Phase 2 | Multiple Myeloma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Alaunos Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Alaunos Therapeutics, Inc.'s (TCRT) pipeline across Phase 3, Phase 2. Its lead program is doxorubicin in combination with palifosfamide-tris (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Alaunos Therapeutics, Inc.'s next FDA catalyst?→
Alaunos Therapeutics, Inc.'s (TCRT) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TCRT biotech catalysts?→
Add TCRT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Alaunos Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.